Guchelaar et al. [16] conducted a crossover pharmacokinetic study to examine the interactions among trifluridine (used in metastatic CRC treatment), metformin, and cimetidine (OCT2/MATE1 inhibitor). Here, SLC47A1 is linked to colorectal carcinoma.